東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Antibody-drug conjugates = the 21st ...

Wang, Jeffrey.

Linked to FindBook

Google Book

Amazon

博客來

Antibody-drug conjugates = the 21st century magic bullets for cancer /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Antibody-drug conjugates/ edited by Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro.
Reminder of title:	the 21st century magic bullets for cancer /
other author:	Wang, Jeffrey.
Published:	Cham :Springer International Publishing : : 2015.,
Description:	x, 252 p. :ill. (some col.), digital ;24 cm.
[NT 15003449]:	1 Antibody-Drug Conjugates: A Historical Review -- 2 Payloads of Antibody-Drug Conjugates -- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy -- 4 Linker Design for Antibody-Drug Conjugates -- 5 Formulation Development for Antibody-Drug Conjugates -- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates -- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates -- 8 Regulatory Considerations -- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy -- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal -- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate -- 12 Ado-Trastuzumab Emtansine -- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer -- 14 Summary and Future Directions.
Contained By:	Springer eBooks
Subject:	Antibody-drug conjugates. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-13081-1
ISBN:	9783319130811 (electronic bk.)

Antibody-drug conjugates = the 21st century magic bullets for cancer /
Antibody-drug conjugatesthe 21st century magic bullets for cancer /[electronic resource] :edited by Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro. - Cham :Springer International Publishing :2015. - x, 252 p. :ill. (some col.), digital ;24 cm. - AAPS advances in the pharmaceutical sciences series,v.172210-7371 ;. - AAPS advances in the pharmaceutical sciences series ;3..

1 Antibody-Drug Conjugates: A Historical Review -- 2 Payloads of Antibody-Drug Conjugates -- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy -- 4 Linker Design for Antibody-Drug Conjugates -- 5 Formulation Development for Antibody-Drug Conjugates -- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates -- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates -- 8 Regulatory Considerations -- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy -- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal -- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate -- 12 Ado-Trastuzumab Emtansine -- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer -- 14 Summary and Future Directions.

This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs) Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011) Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.

ISBN: 9783319130811 (electronic bk.)

Standard No.: 10.1007/978-3-319-13081-1doiSubjects--Topical Terms:

2139008
Antibody-drug conjugates.

LC Class. No.: RS201.A56

Dewey Class. No.: 615.37

Antibody-drug conjugates = the 21st century magic bullets for cancer /
LDR:03299nmm a2200325 a 4500 001 1997699
003 DE-He213
005 20151006164816.0
006 m d
007 cr nn 008maaau
008 151112s2015 gw s 0 eng d
020 $a 9783319130811 (electronic bk.)
020 $a 9783319130804 (paper)
024 7 $a 10.1007/978-3-319-13081-1 $2 doi
035 $a 978-3-319-13081-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RS201.A56
072 7 $a TDCW $2 bicssc
072 7 $a MED072000 $2 bisacsh
082 0 4 $a 615.37 $2 23
090 $a RS201.A56 $b A629 2015
245 0 0 $a Antibody-drug conjugates $h [electronic resource] : $b the 21st century magic bullets for cancer / $c edited by Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a x, 252 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a AAPS advances in the pharmaceutical sciences series, $x 2210-7371 ; $v v.17
505 0 $a 1 Antibody-Drug Conjugates: A Historical Review -- 2 Payloads of Antibody-Drug Conjugates -- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy -- 4 Linker Design for Antibody-Drug Conjugates -- 5 Formulation Development for Antibody-Drug Conjugates -- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates -- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates -- 8 Regulatory Considerations -- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy -- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal -- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate -- 12 Ado-Trastuzumab Emtansine -- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer -- 14 Summary and Future Directions.
520 $a This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs) Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011) Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.
650 0 $a Antibody-drug conjugates. $3 2139008
650 0 $a Antibody-toxin conjugates. $3 2139009
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Pharmaceutical Sciences/Technology. $3 1001579
700 1 $a Wang, Jeffrey. $3 2139005
700 1 $a Shen, Wei-Chiang. $3 2139006
700 1 $a Zaro, Jennica L. $3 2139007
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a AAPS advances in the pharmaceutical sciences series ; $v 3. $3 1566956
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-13081-1
950 $a Biomedical and Life Sciences (Springer-11642)